SPRY
ARS Pharmaceuticals, Inc.NasdaqResearch view
Healthcare · Pharmaceutical Preparations · Small-cap · SEC EDGAR FY 2025-12-31
Price history
Chart: TradingView’s own feed · page prices: 1D EOD🔒 Click to interact · scroll moves the page
Snapshot
SEC EDGAR · FY 2025-12-31SectorHealthcare
Market Cap$422.7M
Enterprise Value$477.7M
Income$-171.3M
Sales$84.3M
Book/sh$1.15
Cash/sh$0.42
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio6.48
Current Ratio7.28
Debt/Eq0.84
EPS (ttm)$-1.74
EPS this Y-2275.0%
EPS past 3/5Y—
Sales past 3/5Y300.1%
EPS Y/Y TTM-2275.0%
Sales Y/Y TTM-5.5%
Shs Outstand99.45M
ROA-52.3%
ROE-149.9%
ROIC-106.0%
Gross Margin—
Oper. Margin-212.9%
Profit Margin-203.3%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue & Earnings — fiscal year
$5.5M
2021
$1.3M
2022
$30,000
2023
$89.1M
2024
$84.3M
2025
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $5.5M | $1.3M | $30,000 | $89.1M | $84.3M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-19.5M | $-35.5M | $-67.5M | $-3.1M | $-179.4M |
| Net Income | $-20.2M | $-34.7M | $-54.4M | $8.0M | $-171.3M |
| Diluted EPS | $-0.70 | $-0.87 | $-0.57 | $0.08 | $-1.74 |
| Operating Cash Flow | $-17.6M | $-40.1M | $-59.3M | $13.5M | $-170.9M |
| Free Cash Flow | $-17.6M | $-40.3M | $-59.4M | $13.0M | $-171.2M |
Deep dive
Computed from the SEC EDGAR multi-year statementsOperating leverage — margins
GrossOperatingNet
FY25 cash-flow waterfall
Cash-flow detail unavailable in this filing.
—
COMMUNITY · $SPRY0 theses
POST YOUR TAKE →Related Stocks
Click to exploreSame Industry · Pharmaceutical Preparations
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.